Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Fish and Richardson
Medtronic
Queensland Health
Mallinckrodt
Argus Health
US Department of Justice
Julphar
Chubb

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021323

« Back to Dashboard

NDA 021323 describes LEXAPRO, which is a drug marketed by Allergan Sales Llc and is included in two NDAs. It is available from fourteen suppliers. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the LEXAPRO profile page.

The generic ingredient in LEXAPRO is escitalopram oxalate. There are twenty-six drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the escitalopram oxalate profile page.
Summary for 021323
Tradename:LEXAPRO
Applicant:Allergan Sales Llc
Ingredient:escitalopram oxalate
Patents:2
Therapeutic Class:Antidepressants
Anxiolytics
Pharmacology for NDA: 021323
Mechanism of ActionSerotonin Uptake Inhibitors
Suppliers and Packaging for NDA: 021323
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LEXAPRO escitalopram oxalate TABLET;ORAL 021323 NDA AUTHORIZED GENERIC Mylan Pharmaceuticals Inc. 0378-3855 N 0378-3855-77
LEXAPRO escitalopram oxalate TABLET;ORAL 021323 NDA AUTHORIZED GENERIC Mylan Pharmaceuticals Inc. 0378-3856 N 0378-3856-10

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE
Approval Date:Aug 14, 2002TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Feb 12, 2023Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Sign UpPatent Expiration:Feb 12, 2023Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE
Approval Date:Aug 14, 2002TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Feb 12, 2023Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021323

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc LEXAPRO escitalopram oxalate TABLET;ORAL 021323-002 Aug 14, 2002 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc LEXAPRO escitalopram oxalate TABLET;ORAL 021323-001 Aug 14, 2002 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc LEXAPRO escitalopram oxalate TABLET;ORAL 021323-003 Aug 14, 2002 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKesson
Citi
Federal Trade Commission
Express Scripts
Baxter
Queensland Health
Johnson and Johnson
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.